The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate

Journal of Virology

Volumn 70, Issue 10, 1996, Pages 6751-6758

  Conley, Anthony J ^a   Kessler II, Joseph A ^a   Boots, Lynn J ^a   McKenna, Philip M ^a   Schleif, William A ^a   Emini, Emilio A ^a   Mark III, George E ^a   Katinger, Hermann ^b   Cobb, E Kathryn ^c   Lunceford, Stacey M ^c   Rouse, Scott R ^c   Murthy, Krishna K ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^c SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY 2F5; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHADENOPATHY; MALE; NONHUMAN; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEROCONVERSION; VIRUS INFECTION; VIRUS ISOLATION; VIRUS REPLICATION;

EID: 9544239346     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.10.6751-6758.1996     Document Type: Article

References (39)

1. Arizono, H., S. Ishii, T. Nagao, S. Kudo, S. Sasaki, S. Kondo, and M. Kiyoki. 1994. Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Arzneim. Forsch. 44:890-898.
2. Arthur, L. O., J. W. Bess, Jr., D. J. Waters, S. W. Pyle, J. C. Kelliher, P. L. Nara, K. Krohn, W. G. Robey, A. J. Langlois, R. C. Gallo, and P. J. Fischinger. 1989. Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120. J. Virol. 63: 5046-5053.
3. Berman, P. W., T. J. Gregory, L. Riddle, G. R. Nakamura, M. A. Champe, J. P. Porter, F. M. Wurm, R. D. Hershberg, E. K. Cobb, and J. W. Eichberg. 1990. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Science 345:622-625.
4. Berman, P. W., K. K. Murthy, T. Wrin, J. C. Vennari, E. K. Cobb, D. J. Eastman, M. Champe, G. R. Nakamura, D. Davison, M. F. Powell, J. Bussiere, D. P. Francis, T. Matthews, T. J. Gregory, and J. F. Obrjeski. 1996. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J. Infect. Dis. 173:52-59.
5. Cao, J., L. Bergeron, E. Helseth, M. Thali, H. Repke, and J. Sodroski. 1193. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type I gp41 envelope glycoprotein. J. Virol. 67:2747-2755.
6. Conley, A. J. Unpublished results.
7. Conley, A. J., P. Conard, S. Bondy, C. A. Dolan, J. Hannah, W. J. Leanza, S. Marburg, M. Rivetna, V. K. Rusiecki, E. E. Sugg, F. Van Middlesworth, S. A. Warne, J. T. Ulrich, J. A. Rudbach, R. L. Tolman, and E. A. Emini. 1994. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens. Vaccine 12:445-451.
8. Conley, A. J., M. K. Gorny, J. A. Kessler II, L. J. Boots, M. Ossorio-Castro, S. Koenig, D. W. Lineberger, E. A. Emini, C. Williams, and S. Zolla-Pazner. 1994. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J. Virol. 68:6994-7000.
9. Conley, A. J., J. A. Kessler II, L. J. Boots, J.-S. Tung, B. A. Arnold, P. M. Keller, A. R. Shaw, and E. A. Emini. 1994. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. USA 91:3348-3352.
10. Ditzel, H. J., J. M. Binley, J. P. Moore, J. Sodroski, N. Sullivan, L. S. W. Sawyer, R. M. Hendry, W.-P. Yang, C. F. Barbas III, and D. R. Burton. 1994. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure. J. Immunol. 154:893-906.
11. SF2. AIDS 9:1313-1322.
12. Emini, E. A., W. A. Schleif, J. H. Nunberg, A. J. Conley, Y. Eda, S. Tokiyoshi, S. D. Putney, S. Matsushita, K. E. Cobb, C. M. Jett, J. W. Eichberg, and K. K. Murthy. 1992. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (London) 355:728-730.
13. Fultz, P. N., P. Nara, F. Barre-Sinoussi, A. Chaput, M. L. Greenberg, E. Muchmore, M.-P. Kieny, and M. Girard. 1992. Vaccine protection of chimpanzees against challenge with HIV-1-infccted peripheral blood mononuclear cells. Science 256:1687-1690.
14. Geffin, R. B., G. B. Scott, M. Melenwick, C. Hutto, S. Lai, L. J. Boots, P. M. McKenna, J. A. Kessler II, and A. J. Conley. Association of antibody reactivity to ELDKWA, a gp41 neutralization epitope, with disease progression in children perinatally infected with human immunodeficiency virus type 1. Submitted for publication.
15. Girard, M., M.-P. Kieny, A. Pinter, F. Barre-Sinoussi, P. Nara, H. Kolbe, K. Kusumi, A. Chaput, T. Reinhart, E. Muchmore, J. Ronco, M. Kaczorek, E. Gomard, J.-C. Gluckman, and P. N. Fultz. 1991. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 88:542-546.
16. Girard, M., B. Meignier, F. Barre-Sinoussi, M.-P. Kieny, T. Matthews, E. Muchmore, P. L. Nara, Q. Wei, L. Rimsky, K. Weinhold, and P. N. Fultz. 1995. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. J. Virol. 69:6239-6248.
17. Gorny, M. K., A. J. Conley, S. Karwowska, A., Buchbinder, J.-Y. Xu, E. A. Emini, S. Koenig, and S. Zolla-Pazner. 1992. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66:7538-7542.
18. Gorny, M. K., J. P. Moore, A. J. Conley, S. Karwowska, J. Sodroski, C. Williams, S. Burda, L. J. Boots, and S. Zolla-Pazner. 1994. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J. Virol. 68:8312-8320.
19. Gorny, M. K., J.-Y. Xu, V. Gianakakos, S. Karwowska, C. Williams, H. W. Sheppard, C. V. Hanson, and S. Zolla-Pazner. 1991. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 88:3238-3242.
20. Heath, S. L., J. G. Tew, J. G. Tew, A. K. Szakal, and G. F. Burton. 1995. Follicular dendritic cells and human immunodeficiency virus infectivity. Nature (London) 377:740-744.
21. Johnson, B. K., G. A. Stone, M.S. Godec, D. M. Asher, D. C. Gajdusek, and C. J. Gibbs, Jr. 1993. Long-term observations of human immunodeficiency virus-infected chimpanzees. AIDS Res. Hum. Retroviruses 9:375-378.
22. Kahn, J. O., K. S. Steimer, J. Baenziger, A.-M. Duliege, M. Feinberg, T. Elbeik, M. Chesney, N. Murcar, D. Chernoff, and F. Sinangil. 1995. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial. J. Infect. Dis. 171:1343-1347.
23. Moore, J. P., A. Trkola, B. Korber, L. J. Boots, J. A. Kessler II, F. E. McCutchan, J. Mascola, D. D. Ho, J. Robinson, and A. J. Conley. 1995. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69:122-130.
24. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Rüker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
25. Murthy, K. K., K. E. Cobb, Z. El-Amad, D. R. Lee, W. Satterfield, M. Kalish, R. C. Kennedy, K. Steimer, A. Schultz, and J. Levy. 1993. Titration of an HIV-1 SF2 virus stock in chimpanzees, poster 80. Presented at the Conference on Advances in AIDS Vaccine Development, Sixth Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS, Alexandria, Va.
26. Neurath, A. R., N. Strick, K. Lin, and S. Jiang. 1995. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions. AIDS Res. Hum. Retroviruses 11:687-696.
27. Pardridge, W. M., J. Buciak, J. Yang, and A. Diagne. 1994. Treatment of human immunodeficiency virus-infected lymphocytes with cationized human immunoglobulins. J. Infect. Dis. 170:563-569.
28. Phillips, A. N. 1996. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 271:497-499.
29. Purtscher, M., A. Trkola, G. Gruber, A. Buchacher, R. Predl, F. Steindl, C. Tauer, R. Berger, N. Barrett, A. Jungbauer, and H. Katinger. 1994. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.AIDS Res. Hum. Retroviruses 10:1651-1658.
30. Safrit, J. T., and R. A. Koup. 1995. The immunology of primary HIV infection: which immune responses control HIV replication? Curr. Opin. Immunol. 7:456-461.
31. Sattentau, Q. J., S. Zolla-Pazner, and P. Poignard. 1995. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206:713-717.
32. Schleif, W. A., K. A. Murthy, V. V. Sardana, C. L. Schneider, V. W. Byrnes, K. E. Cobb, E. Roth, J. A. Wolfgang, J. M. Hoffman, A. M. Smith, K. M. Gelotte, and E. A. Emini. 1994. Attempted prophylaxis of human immunodeficiency virus type 1 infection in chimpanzees with a nonnucleoside reverse transcriptase inhibitor. AIDS Res. Hum. Retroviruses 10:107-110.
33. Schuitemaker, H., L. Meyaard, N. A. Kootstra, R. Dubbes, S. A. Otto, M. Tersmelte, J. L. Heeney, and F. Miedema. 1993. Lack of T cell dysfunction and programmed cell death in human immunodeficiency virus type 1-infected chimpanzees correlates with absence of monocytotropic variants. J. Infect. Dis. 168:1140-1147.
34. MN strain. Proc. Natl. Acad. Sci. USA 87:8597-8601.
35. Shibata, R., M. D. Hoggan, C. Broscius, G. Englund, T. S. Theodore, A. Buckler-White, L. O. Arthur, Z. Israel, A. Schultz, H. C. Lane, and M. A. Martin. 1995. Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo. J. Virol. 69:4453-4462.
36. Stephens, S., S. Emtage, O. Vetterlein, L. Chaplin, C. Bebbington, A. Nesbitt, M. Sopwith, D. Athwal, C. Novack, and M. Bodmer. 1995. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 85:668-674.
37. ten Haaft, P., M. Cornelissen, J. Godsmit, W. Koornstra, R. Dubbes, H. Niphuis, M. Peeters, C. Thiriart, C. Bruek, and J. L. Heeney. 1995. Virus load in chimpanzees infected with human immunodeficiency virus type 1: effect of pre-exposure vaccination. J. Gen. Virol. 76:1015-1020.
38. Wang, C. Y., D. J. Looney, M. L. Li, A. M. Walfleld, J. Ye, B. Hosein, J. P. Tam, and F. Wong-Staal. 1991. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 254:285-288.
39. Yasutomi, Y., S. Koenig, R. M. Woods, J. Madsen, N. M. Wassef, C. R. Alving, H. J. Klein, T. E. Nolan, L. J. Boots, J. A. Kessler, E. A. Emini, A. J. Conley, and N. L. Letvin. 1995. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J. Virol. 69:2279-2284.